29 October 2024 - NICE has published final drat guidance on the use of eplontersen for the treatment of patients with hereditary transthyretin related amyloidosis.

Eplontersen is recommended as an option for the treatment of adults with hereditary transthyretin related amyloidosis with stage 1 or stage 2 polyneuropathy only recommended if AstraZeneca provides it according to the commercial arrangement.

Read NICE final draft guidance